Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Guardado en:

Detalles Bibliográficos
Autores principales:	William L Redmond, Walter J Urba, John Cha, Yoshinobu Koguchi, Brendan D Curti, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, Brian D Piening
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/76e873d352b1483a8641f7e468b7a2f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76e873d352b1483a8641f7e468b7a2f9
record_format	dspace
spelling	oai:doaj.org-article:76e873d352b1483a8641f7e468b7a2f92021-11-24T23:00:05ZTrough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab10.1136/jitc-2021-0026632051-1426https://doaj.org/article/76e873d352b1483a8641f7e468b7a2f92021-10-01T00:00:00Zhttps://jitc.bmj.com/content/9/10/e002663.fullhttps://doaj.org/toc/2051-1426William L RedmondWalter J UrbaJohn ChaYoshinobu KoguchiBrendan D CurtiNoriko IwamotoTakashi ShimadaShu-Ching ChangBrian D PieningBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 William L Redmond Walter J Urba John Cha Yoshinobu Koguchi Brendan D Curti Noriko Iwamoto Takashi Shimada Shu-Ching Chang Brian D Piening Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
format	article
author	William L Redmond Walter J Urba John Cha Yoshinobu Koguchi Brendan D Curti Noriko Iwamoto Takashi Shimada Shu-Ching Chang Brian D Piening
author_facet	William L Redmond Walter J Urba John Cha Yoshinobu Koguchi Brendan D Curti Noriko Iwamoto Takashi Shimada Shu-Ching Chang Brian D Piening
author_sort	William L Redmond
title	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
title_short	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
title_full	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
title_fullStr	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
title_full_unstemmed	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
title_sort	trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/76e873d352b1483a8641f7e468b7a2f9
work_keys_str_mv	AT williamlredmond troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT walterjurba troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT johncha troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT yoshinobukoguchi troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT brendandcurti troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT norikoiwamoto troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT takashishimada troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT shuchingchang troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab AT briandpiening troughlevelsofipilimumabinserumasapotentialbiomarkerofclinicaloutcomesforpatientswithadvancedmelanomaaftertreatmentwithipilimumab
_version_	1718414700747685888

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Ejemplares similares